GB1377608A - Creación de Inventos y Patentes con Inteligencia Artificial

GB1377608A – 3alpha-hydroxy or acyloxy pregnene-21-ethers
– Google Patents

GB1377608A – 3alpha-hydroxy or acyloxy pregnene-21-ethers
– Google Patents
3alpha-hydroxy or acyloxy pregnene-21-ethers

Info

Publication number
GB1377608A

GB1377608A
GB6006570A
GB6006570A
GB1377608A
GB 1377608 A
GB1377608 A
GB 1377608A
GB 6006570 A
GB6006570 A
GB 6006570A
GB 6006570 A
GB6006570 A
GB 6006570A
GB 1377608 A
GB1377608 A
GB 1377608A
Authority
GB
United Kingdom
Prior art keywords
group
hydroxy
pregnane
nitro
oxy
Prior art date
1970-12-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
GB6006570A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Laboratories Ltd

Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1970-12-17
Filing date
1970-12-17
Publication date
1974-12-18

1970-12-17
Application filed by Glaxo Laboratories Ltd
filed
Critical
Glaxo Laboratories Ltd

1970-12-17
Priority to GB6006570A
priority
Critical
patent/GB1377608A/en

1971-12-16
Priority to NL7117249A
priority
patent/NL7117249A/xx

1971-12-16
Priority to US208961A
priority
patent/US3882151A/en

1971-12-16
Priority to CA130,271A
priority
patent/CA995662A/en

1971-12-16
Priority to FR7145226A
priority
patent/FR2118118B1/fr

1971-12-16
Priority to DE19712162594
priority
patent/DE2162594A1/en

1974-12-18
Publication of GB1377608A
publication
Critical
patent/GB1377608A/en

1975-02-20
Priority to US05/551,315
priority
patent/US3969345A/en

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005

C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005

C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005

C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa

C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J5/0023—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa substituted in position 16

C07J5/003—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group including 16-alkylidene substitutes

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group

C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa

C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16

C07J7/003—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE

Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

Y02P20/00—Technologies relating to chemical industry

Y02P20/50—Improvements relating to the production of bulk chemicals

Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

1377608 3α – Hydroxy – pregnane 21 – ethers and their 3-esters GLAXO LABORATORIES Ltd 16 Dec 1971 [17 Dec 1970] 60065/70 Heading C2U [Also in Division A5] Novel 3α-hydroxy steroids of the pregnane and 19-nor-pregnane series and their C 1-5 alkanoyl esters in which the ester group may be substituted by halogen, carboxy or amino, which contain a 21-etherified hydroxy group, a 20- keto or -hydroxy group, a 17α- hydrogen atom and a 5α- or 5#-hydrogen atom are prepared (1) for the 20-ones, by reaction of 21-ols or their reactive derivatives with alcohols or phenols or their reactive derivatives; (2) for the 20-ones of the 5α-pregnane series, by stereospecific reduction of 3-keto compounds using a phosphorous acid ester and an iridium compound, to give the 3α-ols; (3) for the 3α-acyloxy-20- ones, by reaction of the corresponding 3#- hydrocarbonsulphonates with a salt of an appropriate carboxylic acid; or (4) by reaction of 20,21- epoxides (prepared for example by reduction of 20-ones having a readily eliminatable group at the 20-position using a borohydride reducing agent followed by epoxide formation under basic conditions) containing a 3α- or 3#-hydroxy group, a protected 3α-hydroxy group or a keto group with an alcohol or phenol to form a 20-ol- 21-ether, followed when required by oxidation to a 20-keto-21-ether and, when required, by process (2). In process (1) and, as indicated, in process (4) a protected 3α-ol may be used, in which case the protecting group is subsequently removed unless it is a required ester-forming group. Resulting 3α-ols may subsequently be esterified. Products containing a nitro group in the 21-ether group may subsequently be reduced to the corresponding amines; products containing a readily eliminatable group in the 21-ether group may subsequently be reacted with ammonia or an amine to replace the readily eliminatable group by an amino or substituted amino (including heterocyclic amino) group; and products containing a cyano group in the 21-ether group may be solvolysed, preferably in the presence of an alcohol to give the corresponding esters which may subsequently be hydrolysed. Products containing a substituent capable of forming a salt with an acid or base may be salified. The 21-ether substituent is preferably an alkoxy, cycloalkoxy, aralkoxy or aryloxy group which may be substituted. Substituents may be introduced into the steroid nucleus by standard methods before or after 21- ether formation, e.g. a 3α-ol may be tosylated and detosylated to give a #2-compound, this epoxidized and this reacted with a compound ZH or a compound furnishing an anion Z- and a cation to form a 3α-hydroxy-2#-Z-compound directly or via a metal derivative of the 3α-ol. A 20-oxo-#16-steroid may be reacted with a lithium dialkyl cuprate to form a 16α-alkyl-20- oxo steroid. 21-Bromo-steroids used as starting materials are prepared by halogenation of the corresponding 21-unsubstituted-20-keto pregnanes. 21-Hyd roxy steroid starting materials are prepared by lead tetracylate oxidation of the 21-unsubstituted steroids followed by hydrolysis. In these reactions the 3α-hydroxy group is preferably protected, e.g. as a nitro-oxy group. 21 – Hydroxy – 3α – nitro – oxy – 5α – pregnane- 11,20-dione is prepared from 3α-hydroxy-21- acetoxy-5α-pregnane-11,20-dione by nitration followed by hydrolysis. 3α-Nitro-oxy-11-oxo- 5α – androstane – 17# – carboxylic acid is prepared by oxidative degradation of 3α-nitro-oxy- 21-hydroxy-5α-pregnane-11,20-dione; it is subsequently converted to 21-diazo-3α-nitro-oxy- 5α – pregnane – 11,20 – dione via 17# – chlorocarbonyl – 3α – nitro – oxy – 5α – androstan – 11- one. 21-Bromo-3α-nitro-oxy-5α-pregnane-11,20- dione is prepared by nitration of the 3α-ol. The novel 20-keto-steroids are stated to possess anaesthetic, sedative and hypnotic properties, and they may be made up into pharmaceutical compositions with suitable carriers.

GB6006570A
1970-12-17
1970-12-17
3alpha-hydroxy or acyloxy pregnene-21-ethers

Expired

GB1377608A
(en)

Priority Applications (7)

Application Number
Priority Date
Filing Date
Title

GB6006570A

GB1377608A
(en)

1970-12-17
1970-12-17
3alpha-hydroxy or acyloxy pregnene-21-ethers

NL7117249A

NL7117249A
(en)

1970-12-17
1971-12-16

US208961A

US3882151A
(en)

1970-12-17
1971-12-16
Chemical compounds

CA130,271A

CA995662A
(en)

1970-12-17
1971-12-16
Compounds of the pregnane series having useful anaesthetic activity and processes for their preparation

FR7145226A

FR2118118B1
(en)

1970-12-17
1971-12-16

DE19712162594

DE2162594A1
(en)

1970-12-17
1971-12-16

3 alpha-oxygenated pregnan-21-ethers and process for their production

US05/551,315

US3969345A
(en)

1970-12-17
1975-02-20
20β,21-Epoxy-3α-hydroxy-5α-pregnanes and derivatives thereof

Applications Claiming Priority (1)

Application Number
Priority Date
Filing Date
Title

GB6006570A

GB1377608A
(en)

1970-12-17
1970-12-17
3alpha-hydroxy or acyloxy pregnene-21-ethers

Publications (1)

Publication Number
Publication Date

GB1377608A
true

GB1377608A
(en)

1974-12-18

Family
ID=10484939
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

GB6006570A
Expired

GB1377608A
(en)

1970-12-17
1970-12-17
3alpha-hydroxy or acyloxy pregnene-21-ethers

Country Status (6)

Country
Link

US
(1)

US3882151A
(en)

CA
(1)

CA995662A
(en)

DE
(1)

DE2162594A1
(en)

FR
(1)

FR2118118B1
(en)

GB
(1)

GB1377608A
(en)

NL
(1)

NL7117249A
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5593983A
(en)

1993-12-02
1997-01-14
Akzo Nobel N.V.
Substituted 2β-morpholino-androstane derivatives

Families Citing this family (5)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3959260A
(en)

1972-05-05
1976-05-25
Glaxo Laboratories Limited
Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position

US5232917A
(en)

1987-08-25
1993-08-03
University Of Southern California
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series

US6780853B1
(en)

1995-06-06
2004-08-24
Euro-Celtique S.A.
Neuroactive steroids of the androstane and pregnane series

EP1288220A3
(en)

1995-06-06
2004-07-21
Euro-Celtique
Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series

CA2372342A1
(en)

1999-04-29
2000-11-09
Derk J. Hogenkamp
3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3338928A
(en)

1965-09-09
1967-08-29
Syntex Corp
Fused halocyclopropyl steroids

CH534144A
(en)

1967-11-17
1973-02-28
Ciba Geigy Ag
Halopregnadienes antiinflammatory intermediates

CH505080A
(en)

1968-04-22
1971-03-31
Hoffmann La Roche
Hormone active steroids

GB1317184A
(en)

1969-06-20
1973-05-16
Glaxo Lab Ltd
Steroid-containing pharmaceutical preparations

1970

1970-12-17
GB
GB6006570A
patent/GB1377608A/en
not_active
Expired

1971

1971-12-16
CA
CA130,271A
patent/CA995662A/en
not_active
Expired

1971-12-16
NL
NL7117249A
patent/NL7117249A/xx
unknown

1971-12-16
DE
DE19712162594
patent/DE2162594A1/en
active
Pending

1971-12-16
US
US208961A
patent/US3882151A/en
not_active
Expired – Lifetime

1971-12-16
FR
FR7145226A
patent/FR2118118B1/fr
not_active
Expired

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5593983A
(en)

1993-12-02
1997-01-14
Akzo Nobel N.V.
Substituted 2β-morpholino-androstane derivatives

Also Published As

Publication number
Publication date

FR2118118A1
(en)

1972-07-28

CA995662A
(en)

1976-08-24

DE2162594A1
(en)

1972-07-06

FR2118118B1
(en)

1975-11-28

NL7117249A
(en)

1972-06-20

US3882151A
(en)

1975-05-06

Información de contacto